Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
CAR T cell therapy redirects patient T cells to target and eliminate tumor cells. CARs, fusion proteins with antibody-derived antigen recognition and T cell signaling domains, gained FDA approval in 2017 for CD19-targeted therapies in B-cell malignancies. Lentiviral vectors are crucial for CAR transduction in T cell manufacturing, offering stable integration and efficient transduction of dividing/nondividing cells. Creative Biogene provides a comprehensive line of CAR-T lentiviral particles, delivering ready-to-transduce CAR-T lentiviruses with up to 10^9 IFU/mL for accelerated research timelines. For custom lentiviral packaging service, please feel free to contact us.
Key Features of Our CAR-T Lentiviral Particles
The CAR lentiviruses enable stable expression of customized CARs in T cells to redirect specificity against tumor antigens. Potent viral titers allow efficient ex vivo engineering of patient T cells for CAR T cell therapy. The principle involves the transduction of patient T cells with CAR lentiviruses to integrate the engineered receptors and produce CAR T cells targeting malignancies. The high-performance CAR lentivirus platform powers cutting-edge immunotherapy applications from preclinical development to large-scale manufacturing. Creative Biogene's products can promptly support your research in the following areas:
Case Study 1
Researchers utilized lentiviral vectors (LV) to engineer T cells with a chimeric antigen receptor (CAR) targeting Epstein-Barr virus (EBV) gp350 for immunotherapy against nasopharyngeal carcinoma (NPC). The construct, ZT002, expressing scFv 7A1-anti-gp350, was manufactured under good manufacturing practices (GMP) in HEK 293T/17 cells, yielding a high titer (~1x10^8 TU/ml). In preclinical studies using immunocompromised mice, gp350 CAR-T cells demonstrated antitumor responses, tissue distribution, tumor infiltration, and rejection of gp350-expressing tumor cells.
Figure 1. Researchers employed the ZT002 construct for the large-scale production and purification of lentiviral vectors. The 5’ LTR incorporates the EF1α promoter and a WPRE element, enhancing RNA stability upstream of the mutated (Δ) 3’ LTR. (Zhang X, et al., 2023)
Case Study 2
Osteosarcoma (OS) ranks as the predominant bone tumor in children and adolescents, standing as the third most prevalent solid tumor in this demographic. Researchers employed lentiviral vectors to generate B7-H3-CAR T cells or control CAR T cells. The developed orthotopic model, utilizing LM7 OS cells expressing firefly luciferase, reliably mimics human metastatic pediatric osteosarcoma. This model allows real-time imaging of orthotopic tumors and lung metastases. The orthotopic model facilitates the evaluation of safety and efficacy for CAR T cell therapies and other treatment modalities for metastatic osteosarcoma. The lentiviral transduction ensured high-level CAR expression and comparable T cell phenotypes.
Figure 2. Researchers utilized lentiviral vectors for LM7 OS B7-H3 expression, CAR T cell transduction, and evaluated phenotype and in vitro effector function. (Talbot L J, et al., 2021)
Case study 3
B7-H3 is a potential immunotherapy target for solid tumors in pediatric patients, utilizing monoclonal antibodies and T cells equipped with chimeric antigen receptors (CARs). Researchers extensively utilized lentiviral vectors to engineer T cells expressing B7-H3-CARs with various hinge/transmembrane and costimulatory domains (CD8α/CD28, CD8α/41BB, CD28/CD28, CD28/41BB). Despite subtle in vitro differences, CD8α/CD28-CAR T cells consistently outperformed others in animal models, showing significant survival benefits. Surprisingly, adding 41BB signaling to CD8α/CD28-CAR T cells had detrimental effects, while expressing 41BBL on their surface-enhanced tumor-killing abilities. This intricate interplay influenced the selection of CD8α/CD28-CAR T cells expressing 41BBL for early-phase clinical testing, emphasizing the importance of careful domain selection in CAR T cell design.
Figure 3. T cells transduced with a non-functional B7-H3-CAR, featuring a CD8α H/TM domain without a signaling domain, served as the control (CD8α/Δ). (Nguyen P, et al., 2020)
Q: What is the primary application of CAR-T Lentiviral Particles in the context of cellular therapy?
A: CAR-T Lentiviral Particles are used for the genetic modification of T cells to express chimeric antigen receptors (CARs), enhancing their ability to recognize and target specific antigens in cancer cells.
Q: Which components are typically included in CAR-T Lentiviral Particles for effective chimeric antigen receptor expression?
A: CAR-T Lentiviral Particles typically include genetic elements encoding the CAR structure, such as the antigen-binding domain, hinge region, transmembrane domain, and intracellular signaling domains.
Q: In what types of cancer research and treatment are CAR-T Lentiviral Particles commonly employed?
A: CAR-T Lentiviral Particles are commonly used in cancer research and treatment, particularly in developing personalized immunotherapies for hematologic malignancies and solid tumors.
Q: What advantages do CAR-T Lentiviral Particles offer in comparison to other methods of CAR-T cell generation?
A: Lentiviral delivery ensures stable and efficient integration of CAR genes into T cells, providing a reliable method for achieving long-term CAR expression and sustained anti-tumor responses.
| Cat.No. | Product Name | Price |
|---|---|---|
| LV00999Z | mOKT3-scFv[Puro] Lentivirus | Inquiry |
| LV01000Z | mOKT3-scFv[Puro-GFP] Lentivirus | Inquiry |
| LVG00001Z | scFv(CD19)-CD3zeta CAR-T Lentivirus | Inquiry |
| LVG00002Z | scFv(CD19)-41BB-CD3zeta CAR-T Lentivirus | Inquiry |
| LVG00003Z | scFv(CD19)-CD28-CD3zeta CAR-T Lentivirus | Inquiry |
| LVG00004Z | scFv(CD19)-OX40-CD3zeta CAR-T Lentivirus | Inquiry |
| LVG00005Z | scFv(CD19)-CD28-41BB-CD3zeta CAR-T Lentivirus | Inquiry |
| LVG00006Z | scFv(CD19)-CD28-OX40-CD3zeta CAR-T Lentivirus | Inquiry |
| LVG00007Z | scFv(CD20)-CD3zeta CAR-T Lentivirus | Inquiry |
| LVG00008Z | scFv(CD20)-41BB-CD3zeta CAR-T Lentivirus | Inquiry |
| LVG00009Z | scFv(CD20)-CD28-CD3zeta CAR-T Lentivirus | Inquiry |
| LVG00010Z | scFv(CD20)-OX40-CD3zeta CAR-T Lentivirus | Inquiry |
| LVG00011Z | scFv(CD20)-CD28-41BB-CD3zeta CAR-T Lentivirus | Inquiry |
| LVG00012Z | scFv(CD20)-CD28-OX40-CD3zeta CAR-T Lentivirus | Inquiry |
| LVG00013Z | scFv(CD33)-CD3zeta CAR-T Lentivirus | Inquiry |
Copyright © Creative Biogene. All rights reserved.